Pneumonia vaccine catch-up study for kids and teens
Part of Infections clinical trials.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 15 months and 17 years old.
- They must be generally healthy, with no serious medical conditions like immune system problems or seizures.
- They should have records of any earlier pneumococcal vaccines they've received.
- Girls or boys who have reached puberty must agree to use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This trial tests whether giving a pneumococcal vaccine to children hospitalized with severe acute malnutrition can help prevent serious infections. It aims to see if the vaccine is safe and effective in this vulnerable group.
This trial tests a new pneumococcal vaccine (PCV24) in healthy infants and children. It aims to protect against serious infections like pneumonia and meningitis caused by pneumococcal bacteria.
Hear when a new Pneumococcal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.